Crinetics Pharmaceuticals (CRNX) Liabilities and Shareholders Equity (2017 - 2026)

Crinetics Pharmaceuticals' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 2.94% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $5.0 billion (up 7.38% YoY), while the FY2025 annual figure was $1.1 billion, down 21.49% from the prior year.
• Liabilities and Shareholders Equity was $1.4 billion for Q1 2026 at Crinetics Pharmaceuticals, up from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q4 2024 to a low of $293.3 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $825.7 million across 5 years, with a median of $935.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 30.46% in 2023, then jumped 219.02% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $352.2 million in 2022, then jumped by 80.41% to $635.4 million in 2023, then jumped by 125.79% to $1.4 billion in 2024, then fell by 21.49% to $1.1 billion in 2025, then climbed by 24.42% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.